Wang 2017b.

Methods	Study design: Randomised clinical trial Study duration: October 2014 to October 2016 Duration of follow‐up: Not reported Setting: Hospital
Participants	Age (mean ± SD, range): TACE + RFA: 52.07 ± 2.12 years, 34‐75 years; TACE alone: 52.13 ± 2.16 years, 35‐76 years Male (n/total): TACE + RFA: 21/36; TACE alone: 21/36
Interventions	TACE + RFA group (n = 36): TACE: Chemotherapeutic drugs: theprubicin 20 mg, oxaliplatin 150 mg, and mitomycin 8 mg RFA: Ultrasould‐guided RFA. TACE group (n = 36): Chemotherapeutic drugs: theprubicin 20 mg, oxaliplatin 150 mg, and mitomycin 8 mg
Outcomes	Tumour response, classified as complete response, partial response, stable disease, and progression Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.